Skip to main content
Log in

Dose-dependent separation of dopaminergic and adrenergic effects of epinine in healthy volunteers

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

Epinine (N-methyl-dopamine, the active metabolite of ibopamine), is a full agonist at dopamine (DA)-receptors and α- and \-adrenoceptors. To study whether in vivo DA-receptor mediated effects can be separated from α- and \-adrenoceptor effects we compared in 10 male volunteers the effects of i.v. epinine (0.5; 1; 2; 4 μg/kg/min for 15 min each) on DA-receptor (changes in serum prolactin)- and α- and \-adrenoceptor (changes in systolic [Psyst] and diastolic blood pressure [Pdiast] and heart rate)-mediated effects with those of dopamine before and after propranolol (5 mg i.v. 45 min pre-infusion), bisoprolol (15 mg p.o. 2 h preinfusion) and domperidone (10 mg p.o. 1 h pre-infusion). At the 0.5 and 1 μg doses dopamine and epinine did not affect Psyst Pdiast and heart rate but significantly decreased prolactin levels. At the higher dose both dopamine and epinine significantly increased Psyst and heart rate, while only epinine significantly increased Pdiast. In addition both dopamine and epinine significantly increased diuresis and natriuresis; in contrast, only dopamine, but not epinine, dose-dependently increased plasma noradrenaline levels. Domperidone did not affect dopamine- and epinine-evoked blood pressure-and heart rate-changes, but antagonized their prolactin-effects (at least at the lower doses). Bisoprolol and propranolol significantly reduced dopamine-induced Psyst- and heart rate-increases to about the same extent. Propranolol enhanced epinine-induced Psyst-and Pdiast-increases while bisoprolol reduced epinine-evoked Psyst-increase but not Pdiast-increase. Epinine-induced heart rate-increase was abolished by bisoprolol and was converted into a heart rate-decrease by propranolol. We conclude that in 0.5 and 1 μg doses (plasma levels of 20–80 nmol/1) epinine acts only at DA-receptors. Thus, ibopamine in therapeutically recommended doses (3 × 100 mg/day with peak plasma epinine-levels of 50–80 nmol/1) very likely activates only DA-receptors. In higher doses, however, epinine -like dopamine - activates α- and \-adrenoceptors whereby epinine has a stronger α-adrenoceptor agonistic activity than dopamine. Moreover, part of the dopamine-effects are indirect via release of endogenous noradrenaline whereas epinine-effects do not appear to include an indirect component.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Anderson FL, Port JD, Reid BB, Hanson G, Kralios AC, Hershberger RE, Bristow MR (1992) Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 20:800–806

    Google Scholar 

  • Ben-Jonathan N (1985) dopamine; a prolactin-inhibiting hormone, Endocrinol Rev 6:564–589

    Google Scholar 

  • Benker G, Jaspers C, Häusler G, Reinwein D (1990) Control of prolactin secretion - Rev Klin Wochenschr 68:1157–1167

    Google Scholar 

  • Boomsma F, Alberts G, van der Hoorn FAJ, Man in't Veld AJ, Schalekamp MADH (1992) Simultaneous determination of free catecholamines and epinine and estimation of total epinine and dopamine in plasma and urine by high-performance liquid chromatography with fluorometric detection. J Chromatogr 574:109–117

    Google Scholar 

  • Bravo G, Ghyel-Burton J, Jaumin P, Godfraind T (1991) A comparison of the inotropic effects of dopamine and epinine in human isolated cardiac preparations. J Pharmacol Exp Ther 257: 439–443

    Google Scholar 

  • Brodde O-E, Inui J, Motomura S, Schümann HJ (1980) The mode of direct action of dopamine in the rabbit heart. J Cardiovasc Pharmacol 2:567–582

    Google Scholar 

  • Brodde O-E, Motomura S, Schümann HJ (1979) Studies on the mechanism of the positive inotropic action evoked by epinine on the rabbit isolated papillary muscle at different rates of beating. Clin Exp Pharmacol Physiol 6:41–51

    Google Scholar 

  • Brodde O-E, Klusmann I, Wojcik M, Man in't Veld AJ, Boomsma F, Michel MC (1993) Lack of desensitization of α- and \-adrenoceptor function during chronic treatment of healthy volunteers with ibopamine, an orally active dopamine receptor agonist. Eur J Clin Pharmacol 44:283–286

    Google Scholar 

  • Brodde O-E (1990) Affinities of dopamine agonists and antagonists for peripheral dopamine receptors. In: JP Hieble (ed) Cardiovascular function of peripheral dopamine receptors. Marcel Dekker, New York Basel, pp 27–74

    Google Scholar 

  • Brodde O-E (1986) Bisoprolol (EMD 33512), a highly selective \1-adrenoceptor antagonist: in vitro and in vivo studies. J Cardiovasc Pharmacol 11 [Suppl 11]:S29-S35

    Google Scholar 

  • Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS (1982) Domperidone. Drugs 24:360–400

    Google Scholar 

  • Brown L, Lorenz B, Erdmann E (1985) The inotropic effects of dopamine and its precursor levodopa on isolated human ventricular myocardium. Klin Wochenschr 63:1117–1123

    Google Scholar 

  • Carey RM (1990) Dopaminergic control of aldosterone secretion. In: Hieble JP (ed) Cardiovascular function of peripheral dopamine receptors. Marcel Dekker, New York Basel, pp 297–314

    Google Scholar 

  • Casagrande C, Merlo L, Ferrini R, Miragoli G, Semeraro C (1989) Cardiovascular and renal action of dopaminergic prodrugs. J Cardiovasc Pharmacol 14 [Suppl 8]:S40-S59

    Google Scholar 

  • Daul A, Hermes U, Schäfers RF, Wenzel R, Von Birgelen C, Brodde O-E (1995) The \-adrenoceptor subtype(s) mediating adrenaline-and dobutamine-induced blood pressure and heart rate changes in healthy volunteers. Int J Clin Pharmacol Ther 33:140–148

    Google Scholar 

  • Deighton NM, Motomura S, Bals S, Zerkowski H-R, Brodde O-E (1992) Characterization of the beta adrenoceptor subtype(s) mediating the positive inotropic effects of epinine, dopamine, dobutamine, denopamine and xamoterol in isolated human right atrium. J Pharmacol Exp Ther 262:532–538

    Google Scholar 

  • English TAH, Gristwood RW, Owen RAA, Sampford KA, Wallwork J (1986) Effects of dopamine on human ventricle in vitro: Comparison with effects of isoprenaline, epinine and ibopamine (Abstract). Br J Pharmacol 87: [Suppl] 203 P

    Google Scholar 

  • Ensinger H, Lindner KH, Goertz A, Grünert A, Ahnefeld FW, Georgieff M (1993) Metabolic and haemodynamic effects of dopamine plus domperidone in volunteers. Res Exp Med 193:241–254

    Google Scholar 

  • Girbes ARJ, Van Veldhuisen DJ, Grevink RG, Smit AJ, Reitsma WD (1992) Effects of ibopamine on exercise induced increase in norepinephrine in normal men. J Cardiovasc Pharmacol 19:371–374

    Google Scholar 

  • Goldberg LI, Kohli JD (1983) Peripheral dopamine receptors: a classification based on potency series and specific antagonism. Trends Pharmacol Sci 4:64–66

    Google Scholar 

  • Goldberg LI (1972) Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 25:1–29

    Google Scholar 

  • Goldberg LI (1989) The role of dopamine receptors in the treatment of congestive heart failure. J Cardiovasc Pharmacol 14 [Suppl 5]:S19-S27

    Google Scholar 

  • Hasenfuss G, Kasper W, Meinertz T, Busch W, Lehmann M, Kruse T, Hofmann T, Revenaugh M, Holubarsch C, Just H (1987) Evaluation of long-term oral levodopa therapy in chronic congestive heart failure. Klin Wochenschr 65:1087–1094

    Google Scholar 

  • Henwood JM, Todd PA (1989) Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 36:11–31

    Google Scholar 

  • Hilditch A, Drew GM (1985) Peripheral dopamine receptor subtypes — a closed look. Trends Pharmacol Sci 6:396–400

    Google Scholar 

  • Huang Y-C, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JP (1986) Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J Clin Pharmacol 26:628–632

    Google Scholar 

  • Katz AM (1986) Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 73 [Suppl III]: III-184-III-190

    Google Scholar 

  • Kayanakis JG and the European Ibopamine Study Group (1991) Six-month treatment of congestive heart failure with ibopamine. A double-blind randomized, placebo-controlled, multicenter trial. Am J Noninvasice Cardiol 5:35–41

    Google Scholar 

  • Kohli JD, Glock D, Goldberg LI (1983) Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol 89:137–141

    Google Scholar 

  • Lee MR (1993) Dopamine and the kidney: ten years on. Clin Sci 84:357–375

    Google Scholar 

  • Levinson PD, Goldstein DS, Munson PJ, Gill JR, Keiser HR (1985) Endocrine, renal and hemodynamic responses to graded dopamine infusions in normal men. J Clin Endocrinol Metab 60:821–826

    Google Scholar 

  • Lokhandwala MF, Amenta F (1991) Anatomical distribution and function of dopamine receptors in the kidney. FASEB J 5:3023–3030

    Google Scholar 

  • Lokhandwala MF, Barrett RJ (1982) Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications. J Anton Pharmacol 3:189–215

    Google Scholar 

  • Lorenzi M, Karam JH, Tsalikian E, Bohannon NV, Gerich JE, Forsham PH (1979) Dopamine during α- or β-adrenergic blockade in man. J Clin Invest 63:310–317

    Google Scholar 

  • Mugelli A, Ledda F, Mantelli L, Torrini M, Maccioni T (1977) Studies on the positive inotropic effect of dopamine in the guinea-pig heart. Naunyn Schmiedeberg's Arch Pharmacol 301:49–55

    Google Scholar 

  • Nichols AJ, Ruffolo RR (1987) Evulation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparison with epinine and dopamine. J Pharmacol Exp Ther 242:455–463

    Google Scholar 

  • Os I, Kjeldsen SE, Westheim A, Lande K, Norman N, Hjermann I, Eide I (1987) Endocrine and haemodynamic responses to graded dopamine infusion in essential hypertension. Scand J Clin Lab Invest 47:371–377

    Google Scholar 

  • Packer M (1992) Pathophysiology of chronic heart failure. Lancet 340:88–92

    Google Scholar 

  • Pernet A, Hammond VA, Blesa-Malpica G, Burrin J, Orskov H, Alberti KGMM, Johnston DG (1984) The metabolic effects of dopamine in man. Eur J Clin Pharmacol 26:23–28

    Google Scholar 

  • Port JD, Gilbert EM, Larrabee P, Mealey P, Volkmann K, Ginsburg R, Hershberger RE, Murray J, Bristow MR (1990) Neurotransmitter depletion compromises the ability of indirect-acting amines to proviede inotropic support in the failing human heart. Circulation 81:929–938

    Google Scholar 

  • Rajfer SI, Fetima RD (1990) Role of dopamine receptors and the utility of dopamine agonists in heart failure. Circulation 82:97–102

    Google Scholar 

  • Rajfer SI, Rossen JD, Douglas FL, Goldberg LL Karrison T (1986) Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyl-dopamine and to plasma catecholamine levels. Circulation 73:740–748

    Google Scholar 

  • Rajfer SI, Rossen JD, Nemanich JW, Douglas FL, Davis F, Osinski J (1987) Sustaind hemodynamic improvement during long-term therapy with levodopa in heart failure: role of plasma catecholamines. J Am Coll Cardiol 10:1286–1293

    Google Scholar 

  • Rousseau MF, Raigoso J, van Eyll Ch, Van Mechelen H, Musso NR, Lotti G, Pouleur H (1992) Effects of intravenous epinine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure. J Cardiovasc Pharmacol 19:155–162

    Google Scholar 

  • Schwinger RHG, Böhm M, Schulz Ch, Schmidt U, Schmid B, Dienemann H, Reichart B, Erdmann E (1993) Cardiac inotropic as well as coronary and pulmonary artery actions of epinine in human isolated tissues. J Pharmacol Exper Ther 265:346–357

    Google Scholar 

  • Smit AJ, Meijer S, Wesseling H, Donker AJM, Reitsma WD (1988) Effect of metoclopramide on dopamine-induced changes in renal function in healthy controls and in patients with renal disease. Clin Sci 75:421–428

    Google Scholar 

  • Spencer C, Faulds D, Fitton A (1993) Ibopamine. Drugs & Aging 3:556–584

    Google Scholar 

  • Taylor SH (1989) Pharmacotherapeutic profile of ibopamine in heart failure. J Cardiovasc Pharmacol 14 [Suppl. 8]:5118–5123

    Google Scholar 

  • Van Veldhuisen DJ, Girbes ARJ, Crijns HJ, Smit AJ, Van Gilst WH, Lie KI (1991) The oral dopamine agonist, ibopamine, in normal man: effects on rhythm, heart rate, blood pressure and catecholamines. Int J Clin Pharmacol Res 11:159–165

    Google Scholar 

  • Willems JL, Buylaert WA, Lefebvre RA, Bogaert MG (1985) Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev 37:165–216

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Daul, A., Elter-Schulz, M., Poller, U. et al. Dose-dependent separation of dopaminergic and adrenergic effects of epinine in healthy volunteers. Naunyn-Schmiedeberg's Arch Pharmacol 352, 429–437 (1995). https://doi.org/10.1007/BF00172781

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00172781

Key words

Navigation